Hypertension and Cardiovascular Risk Factors

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• - Patients who give consent

• Men and women 18 to 80 years of age

• Patients with hypertension (systolic >159 mm, diastolic >100 mm)

• Patients meeting laboratory criteria

Exclusion Criteria:

• - Pregnant women

• Women not using approved contraception methods

• Secondary hypertension

Other protocol-defined exclusion criteria may apply.